Infection of murine BM, followed by transplantation of the infected cells into lethally irradiated recipient mice is a critical assay for understanding how oncogenes alter leukemia progression and hematopoietic lineage decisions. Conventional wisdom suggests that donor mice should be treated with 5-fluorouracil (5FU) and harvested BM cells cultured in the presence of cytokines for up to 5 days to enrich for the stem cells for these experiments to be successful. However, we show that regardless of how donor BM is prepared, the leukemic phenotypes and disease progression is dependent only on the oncogenic driver expressed in the infected cells.
Our laboratory has been interested in the role of oncogenic combinations in the initiation, progression and maintenance of leukemia. [1] [2] [3] To this end, we have adopted a BM infection and transplantation model as a rapid, reliable and flexible model system. Penetrance, latency and cell surface phenotype of leukemias differ depending on the oncogenic combinations being tested. Published protocols suggest that mice should be treated with 150 mg/kg of 5FU for at least 5 days followed by harvesting cells from bones and then culturing the cells in the presence of SCF, IL-3 and IL-6 for a minimum of 2 days. 4 At the end of the culture period, the cells are infected with viral supernatant by centrifugation in the presence of polybrene. Some protocols call for multiple rounds of infection over multiple days. Overall, this protocol is time consuming and costly.
We were curious as to whether this lengthy protocol was necessary and if deviation from this protocol would affect the penetrance, latency or phenotype of the resulting leukemias. To determine if the preparation of the donor BM affects the outcome of the murine leukemias, we tested three different preparations of donor BM. The first was prepared exactly as described above whereby donor Tet-O-MYC mice were treated with 150 mg/kg of 5FU, marrow was harvested from femurs and tibias and then www.nature.com/bmt cultured for 48 h in the presence of SCF, IL-3 and IL-6 (5FU; culture). For the second condition, mice were treated with 150 mg/kg of 5FU for 5 days and the BM cells were harvested and infected on the same day (5FU; no culture) eliminating costly cytokines, and the third condition consisted of harvesting BM from non-treated mice and infecting the cells the same day they were harvested (no FU; no culture), eliminating both costly cytokines and lengthy pretreatments. On the day of infection, BM cells from all three conditions were analyzed by flow cytometry for cell surface markers (Figure 1a) or were seeded into methylcellulose containing cytokines to determine the colony-forming capacity of the cells (Figure 1b) . Flow cytometric analysis demonstrated changes in the cell surface phenotypes of the BM cells consistent with 5FU or cytokine treatment enriching for populations of cells with more immature cell surface markers. Consistent with this observation, seeding 10 000 cells from each of the conditions showed dramatically different numbers of colony-forming cells. The BM cells harvested from the 5FU-treated mice that were then cultured in the presence of cytokines for 48 h had an increased number of colony-forming units. These data together are consistent with the fact that pretreatment of the cells with 5FU, in addition to culturing in the presence of SCF, IL-3 and IL-6, enriches for a population of cells with stem-like properties.
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Left column represent each individual mouse within the three BM preparation protocols. TOM-114 to TOM-152 are mice that received cells expressing MYC and BCLw; N16 to N33 are mice that received cells expressing the intracellular domain of Notch1 (N ic ) a A mouse that developed hind limb paralysis. Survival (days) indicates the number of days post transplantation of infected cells that the mouse survived. Splenocytes (% total after lysis of RBC), indicates the percentage of total splenocytes that stained positive with the indicated antibody. Total % is the sum of all antibodies used for analysis. The total % is higher than 100% due to rounding of percentages to the nearest whole number.
Letter to the Editor retrovirus expressing BCLw and tTA (MIT-BCLw), which leads to expression of MYC and BCLw, all required euthanasia by the 23rd day (Figure 1c) . Splenocytes from all animals were analyzed by flow cytometry to determine the cell surface phenotype of the leukemic cells. Animals receiving cells expressing N ic succumbed to a disease that included an enlarged spleen, liver, thymus and lymph nodes, whereas mice receiving cells expressing MYC and BCLw never presented with enlarged lymph nodes or thymus and quite often developed hind limb paralysis (Table 1) . Flow cytometry of the splenocytes of the N ic expressing leukemic mice showed a universal increase in CD4/CD8 double positive T-cells in the spleen (Table 1 ). In contrast, MYC/BCLw-expressing leukemic cells expressed the myeloid markers GR1/CD11b (Table 1 ). The combination of myeloid, T-cell, B-cell and erythroid cells in the analyzed spleen accounted for more than 90% of the cells in almost every case examined, suggesting that we have appropriately covered all relevant cell populations with our analyses.
There are two important points worth noting for this particular protocol. First, herein, we use retroviruses that should be ineffective at infecting quiescent or non-replicating cells. However, we do not see major differences whether the target cells are prestimulated (via cytokine treatment) or following enrichment for progenitor populations (via 5-FU treatment of the mice). One likely explanation for this is that the cells are transplanted into lethally irradiated recipient mice 4 h post irradiation. Following these doses of irradiation, it is known to cause a condition known as 'cytokine storm', which would likely lead to a marked increase in the proliferation of the transplanted cells immediately following introduction into the recipient mice. We feel that the use of lentiviruses would be equally effective in this protocol due to their ability to infect quiescent and non-replicating cells. The second point involves the specific oncogenic combinations used. The two genetic combinations used herein are very potent combinations known to induce a polyclonal disease. Although we have used this protocol to test many oncogenic combinations, it may be true that drastic differences may appear if the second or third mutations are selected during leukemogenesis. Also, as this protocol does not take into consideration optimizing infection efficiencies, it is not ideal for the study of individual infected cells or early leukemogenic changes, such as early effects on hematopoiesis. Taken together, this protocol should reduce costs and time, and increase knowledge gained from the studies of oncogenic combinations in leukemia.
